Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Takeda Pharmaceutical Co. Ltd.

www.takeda.com

Latest From Takeda Pharmaceutical Co. Ltd.

Deal Watch: Takeda Signs Broad Cancer Collaboration With Nektar

Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijen.

Deals M & A

Contrave Rxs Jump In Q1, But TV Commercial Runs Afoul Of FDA

Orexigen touts 39% growth in US sales of its obesity drug; agency objects to advertisement for excluding risk information.

FDA Advertising, Marketing & Sales

Contrave TV Ad's Slimmed Down Adverse Events Draw FDA Rebuke

Referencing opioids and suicidal thoughts is not sufficient, US regulators say; letter comes as Orexigen has seen an upsurge in Contrave prescriptions.

Advertising, Marketing & Sales Regulation

China Embracing Microbiome Research Through Programs, Partnerships

NuBiyota is setting up a local presence to tap into China’s growing commitment to developing new therapeutics based on the microbiome, an area the country is increasingly supporting through central initiatives as part of a national precision medicine program, and where new partnerships are emerging.

China Research & Development
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register